ANI PHARMACEUTICALS INC
ANIP · XNASCIK 1023024fmd_0GJ39W8RQH900CK7AK399T4H13Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 129 | 177 | 202 | 207 | 208 | 216 | 316 | 487 | 614 | 883 |
| Total interest income | – | – | – | – | – | – | 0 | 9 | 16 | 13 |
| Net interest income | – | – | – | – | – | – | (28) | (27) | (18) | (20) |
| Cost of revenue | 49 | 79 | 73 | 63 | 87 | – | – | – | – | – |
| Gross profit | 80 | 98 | 129 | 143 | 121 | – | – | – | – | – |
| Research and development | 3 | 9 | 15 | 20 | 16 | 11 | 22 | 34 | 45 | 52 |
| Selling, general and administrative | 28 | 32 | 44 | 56 | 65 | 84 | 124 | 162 | 250 | 318 |
| Operating income | 20 | 28 | 35 | 16 | (16) | (40) | (35) | 47 | 1 | 111 |
| Interest expense | 11 | 11 | 15 | 13 | 9 | 12 | 29 | 36 | 34 | 33 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | 0 | (1) | (0) | (0) | (4) | 1 | (0) | (4) | 2 |
| Income before taxes | 9 | 16 | 20 | 3 | (26) | (56) | (63) | 20 | (22) | 96 |
| Income tax expense | 5 | 17 | 5 | (3) | (3) | (13) | (15) | 1 | (4) | 17 |
| Net income from continuing operations | 4 | (1) | 15 | 6 | (23) | (43) | (48) | 19 | (19) | 78 |
| Net income | 4 | (1) | 15 | 6 | (23) | (43) | (48) | 19 | (19) | 78 |
| Net income to common shareholders | 4 | (1) | 15 | 6 | (23) | (43) | (50) | 17 | (20) | 77 |